Cinven takes majority stake in Labco

The acquisition of Labco by funds managed by Cinven follows the strategic withdrawal of the company’s planned Initial Public Offering (IPO) on Euronext Paris. This transaction allowed for the total rationalization of a complex shareholding structure previously split between financial investors (3i, TCR Capital, NiXen, CM-CIC), founders, and a large group of independent biologists. The strategic rationale for the deal is rooted in the creation of a leading pan-European platform within the consolidating medical biology sector. By moving from a fragmented ownership model to a single institutional sponsor, the group gains the agility necessary to pursue a rapid international expansion strategy. The acquirer implemented an innovative financing structure to maintain existing bond facilities while providing immediate liquidity to the historical stakeholders. This operation took place during a record year for healthcare M&A and was designed to enhance the group's competitive positioning in bidding for hospital outsourcing contracts. The new governance model ensures long-term alignment with the group’s industrial objectives while strictly adhering to local regulatory frameworks regarding the professional ownership of medical laboratories. This partnership positions the group as a cornerstone for future consolidation in the diagnostic services market across Europe.

The acquisition of Labco is part of the growth strategy of Cinven, which already has several external growth operations under its belt, notably Skandia Germany & Austria in 2014.